Innoveren Scientific Inc.
IVRN
$0.0002
$0.000.00%
OTC PK
| 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | 09/30/2022 | |
|---|---|---|---|---|---|
| Revenue | -100.00% | -100.00% | -95.42% | -71.86% | -55.57% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -100.00% | -100.00% | -95.42% | -71.86% | -55.57% |
| Cost of Revenue | -99.63% | -99.75% | -94.75% | -83.31% | -62.39% |
| Gross Profit | -100.20% | -100.12% | -95.81% | -62.95% | -50.88% |
| SG&A Expenses | -38.19% | -47.26% | -51.25% | -44.36% | -52.72% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -42.70% | -51.78% | -55.41% | -48.39% | -53.19% |
| Operating Income | 27.16% | 34.65% | 41.30% | 41.11% | 52.50% |
| Income Before Tax | 65.89% | 35.86% | -16.67% | -114.61% | -70.21% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 65.89% | 35.86% | -16.67% | -114.61% | -70.21% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 65.89% | 35.86% | -16.67% | -114.61% | -70.21% |
| EBIT | 27.16% | 34.65% | 41.30% | 41.11% | 52.50% |
| EBITDA | 27.17% | 34.83% | 41.48% | 41.21% | 52.49% |
| EPS Basic | 86.26% | 68.29% | 41.83% | -35.17% | -12.30% |
| Normalized Basic EPS | 87.36% | 81.62% | 83.73% | 21.81% | 28.81% |
| EPS Diluted | 85.15% | 67.08% | 41.83% | -35.17% | -12.30% |
| Normalized Diluted EPS | 88.31% | 82.44% | 83.73% | 21.81% | 28.81% |
| Average Basic Shares Outstanding | 179.05% | 178.39% | 148.60% | 87.70% | 56.29% |
| Average Diluted Shares Outstanding | 231.54% | 241.56% | 148.60% | 87.70% | 56.29% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |